drugset / Trial / NCT06441643

Next Generation Rocklatan

NCT06441643

Phase 2 Completed 426 enrolled Alcon Research
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Timeline

Start
2024-09-04
Primary completion
2025-11-14
Completion
2025-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject AR-17043 Unknown Other
Comparator Latanoprost Small molecule 0.005 % Other
Comparator Netarsudil Small molecule 0.02 % Other